Ginkgo Biloba Extract Is Comparable With Donepezil in Improving Functional Recovery in Alzheimer’s Disease: Results From a Multilevel Characterized Study Based on Clinical Features and Resting-State Functional Magnetic Resonance Imaging

Yu Zheng, Yi Xie, Ming Qi, Ling Zhang, Wei Wang, Wanrong Zhang, Liju Sha, Jiawen Wu, Wanting Li, Ting WuFrontiers in Pharmacology 2021 · DOI

Abstract

Background: Ginkgo biloba extract (GBE) and donepezil have been reported to be effective in patients with Alzheimer's disease (AD). Nonetheless, how these drugs impact spontaneous brain activities and how they consequently improve functional recovery are currently unclear. Objectives: This study was to explore the efficacy of GBE vs. donepezil and their add-on efficacy on functional recovery and the adaption of spontaneous brain activities following pharmacologic treatment in patients with AD. Methods: Patients with AD were enrolled and assigned to the GBE group (n = 50), the donepezil group (n = 50), or the combined group (n = 50). Neuropsychological assessments, including minimum mental state examination (MMSE), Alzheimer's disease assessment scale-cognition (ADAS-Cog), instrumental activity of daily living (IADL), geriatric depression scale (GDS), neuropsychiatric inventory (NPI), and quality of life in Alzheimer's disease (QOL-AD), were conducted at baseline, 1 month, 3 months, and 6 months. Resting-state functional magnetic resonance imaging (rs-fMRI) was collected to compare the amplitude of low-frequency fluctuation (ALFF), percent amplitude of fluctuation (PerAF), regional homogeneity (ReHo), and degree centrality (DC) at baseline and 6 months. Results: No major significant differences were detected in all comparisons between groups across all follow-up time points. For intragroup comparison, MMSE and ADAS-Cog scores differed significantly across all follow-ups in three groups. The combined group showed significant improvement of GDS scores between baseline and 6 months (p = 0.007). The GBE group (p = 0.044) and donepezil group (p = 0.012) demonstrated significant improvement of NPI scores between baseline and 6 months. Significant correlations were observed between IADL and ALFF in the right gyrus rectus (p = 0.03) and in the left superior cerebellum gyrus (p = 0.01), between GDS and ALFF in the right middle temporal gyrus (p = 0.01), between NPI and PerAF in the left fusiform gyrus (p = 0.03), and between MMSE and ReHo in right superior frontal gyrus (p = 0.04). Conclusion: GBE was comparable with donepezil in the improvement of functional recovery in patients with AD while the combined application of GBE and donepezil seems unnecessary. GBE-mediated improvement of functional recovery was characterized by decreased ALFF values in the right gyrus rectus and decreased PerAF values in the left fusiform gyrus. These featured variations of imaging metrics in specific brain regions may serve as biomarkers in the monitoring of the therapeutic efficacy of GBE.

Introduction

Alzheimer’s Disease (AD) remains a primary challenge in neurodegenerative medicine, characterized by progressive cognitive decline and loss of functional independence. While acetylcholinesterase inhibitors like Donepezil are standard treatments, their efficacy varies and side effects can be limiting. Ginkgo Biloba Extract (GBE) has emerged as a potential alternative or adjunct therapy. This study provides a head-to-head comparison of GBE and Donepezil, utilizing both clinical assessments and advanced neuroimaging to evaluate their impact on functional recovery and brain activity.

Methods

The researchers conducted a 6-month, three-arm parallel group study involving 150 AD patients. Participants were equally divided into three treatment arms: GBE (50), Donepezil (50), and a Combined therapy group (50).

Study flow diagram showing patient recruitment, group allocation, and follow-up.

Clinical efficacy was measured using a comprehensive battery of tests, including the MMSE for general cognition, ADAS-Cog for specific cognitive deficits, and IADL for daily living skills. Additionally, resting-state functional Magnetic Resonance Imaging (rs-fMRI) was employed to analyze spontaneous brain activity through metrics such as the Amplitude of Low-Frequency Fluctuation (ALFF) and Regional Homogeneity (ReHo).

Results

Across the 6-month study period, all three treatment groups demonstrated significant improvements in cognitive scores (MMSE and ADAS-Cog). Crucially, intergroup comparisons revealed no major statistical differences in efficacy between GBE and Donepezil, or between the monotherapy groups and the combined therapy group.

Comparison of clinical outcomes between GBE, Donepezil, and Combined treatment groups over 6 months.

The study also identified significant correlations between clinical improvement and specific brain activity changes. In the GBE group, improved daily living (IADL) scores were positively correlated with ALFF changes in the right gyrus rectus (p = 0.03). Furthermore, general cognitive improvement (MMSE) correlated with ReHo changes in the right superior frontal gyrus (p = 0.04). These findings suggest that GBE-mediated recovery is associated with distinct neurophysiological adaptations.

Discussion and Conclusion

The results indicate that GBE is comparable to Donepezil in improving functional recovery for patients with AD. Furthermore, the lack of significant additional benefit in the combined group suggests that dual-drug regimens may be unnecessary for many patients.

The identification of specific activity changes in regions like the gyrus rectus and fusiform gyrus provides potential objective biomarkers for monitoring treatment response. While limited by a relatively small fMRI-qualified sample size and a 6-month duration, this study supports GBE as a viable therapeutic option for Alzheimer's management. Future research should focus on longer-term outcomes and the impact of these treatments on large-scale brain networks.

Summary updated

Abstract

<b>Background:</b> Ginkgo biloba extract (GBE) and donepezil have been reported to be effective in patients with Alzheimer's disease (AD). Nonetheless, how these drugs impact spontaneous brain activities and how they consequently improve functional recovery are currently unclear. <b>Objectives:</b> This study was to explore the efficacy of GBE vs. donepezil and their add-on efficacy on functional recovery and the adaption of spontaneous brain activities following pharmacologic treatment in patients with AD. <b>Methods:</b> Patients with AD were enrolled and assigned to the GBE group (<i>n</i> = 50), the donepezil group (<i>n</i> = 50), or the combined group (<i>n</i> = 50). Neuropsychological assessments, including minimum mental state examination (MMSE), Alzheimer's disease assessment scale-cognition (ADAS-Cog), instrumental activity of daily living (IADL), geriatric depression scale (GDS), neuropsychiatric inventory (NPI), and quality of life in Alzheimer's disease (QOL-AD), were conducted at baseline, 1 month, 3 months, and 6 months. Resting-state functional magnetic resonance imaging (rs-fMRI) was collected to compare the amplitude of low-frequency fluctuation (ALFF), percent amplitude of fluctuation (PerAF), regional homogeneity (ReHo), and degree centrality (DC) at baseline and 6 months. <b>Results:</b> No major significant differences were detected in all comparisons between groups across all follow-up time points. For intragroup comparison, MMSE and ADAS-Cog scores differed significantly across all follow-ups in three groups. The combined group showed significant improvement of GDS scores between baseline and 6 months (<i>p</i> = 0.007). The GBE group (<i>p</i> = 0.044) and donepezil group (<i>p</i> = 0.012) demonstrated significant improvement of NPI scores between baseline and 6 months. Significant correlations were observed between IADL and ALFF in the right gyrus rectus (<i>p</i> = 0.03) and in the left superior cerebellum gyrus (<i>p</i> = 0.01), between GDS and ALFF in the right middle temporal gyrus (<i>p</i> = 0.01), between NPI and PerAF in the left fusiform gyrus (<i>p</i> = 0.03), and between MMSE and ReHo in right superior frontal gyrus (<i>p</i> = 0.04). <b>Conclusion:</b> GBE was comparable with donepezil in the improvement of functional recovery in patients with AD while the combined application of GBE and donepezil seems unnecessary. GBE-mediated improvement of functional recovery was characterized by decreased ALFF values in the right gyrus rectus and decreased PerAF values in the left fusiform gyrus. These featured variations of imaging metrics in specific brain regions may serve as biomarkers in the monitoring of the therapeutic efficacy of GBE.
BibTeX
@inproceedings{zheng2021ginkgo,
  author = {Yu Zheng and Yi Xie and Ming Qi and Ling Zhang and Wei Wang and Wanrong Zhang and Liju Sha and Jiawen Wu and Wanting Li and Ting Wu},
  title = {{Ginkgo Biloba Extract Is Comparable With Donepezil in Improving Functional Recovery in Alzheimer’s Disease: Results From a Multilevel Characterized Study Based on Clinical Features and Resting-State Functional Magnetic Resonance Imaging}},
  booktitle = {Frontiers in Pharmacology},
  year = {2021},
  doi = {10.3389/fphar.2021.721216},
}
Figure